The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Provider roles in the recruitment of underrepresented populations to cancer clinical trials
Abstract
BACKGROUND.: Providers play a vital role in the successful recruitment of underrepresented patients to cancer clinical trials because they often introduce the opportunity of clinical trials. The purpose of the current systematic review was to describe provider‐related factors influencing recruitment of underrepresented populations to cancer clinical trials. METHODS.: To find original studies on the recruitment of underrepresented populations to cancer clinical trials, electronic databases from January 1966 to December 2005 were searched; hand‐searched titles in 34 journals from January 2003 to January 2006; and reference lists were examined of eligible articles. Title and abstract reviews were conducted to identify relevant studies. Potential articles were then abstracted using a structured instrument and a serial review process by 2 investigators. RESULTS.: Eighteen studies were eligible for review: 13 targeted healthcare providers, 3 targeted patients/participants, and 2 targeted both providers and patients. The study designs included randomized controlled trial, concurrent controlled trial, case‐control, descriptive, and qualitative. A lack of available protocols and/or a lack of provider awareness about clinical trials prevented providers from discussing the opportunity of clinical trials in 2 studies. In 14 studies, patient accrual was affected by provider attitudinal barriers relating to patient adherence to the study protocol, patient mistrust of research, patient costs, data collection costs, and/or patient eligibility. Providers' communication methods were barriers in 5 studies and promoters in 1 study. CONCLUSIONS.: A heterogeneous body of evidence suggests that several provider‐related factors influence recruitment of underrepresented groups to clinical trials. Future recruitment efforts should address these factors. Cancer 2007;109:465–476. © 2007 American Cancer Society.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Grading quality of evidence and strength of recommendations
(2004) · BMJ · doi:10.1136/bmj.328.7454.1490 · Cited by 8,477
Cited by
Bonevski, B., Randell, M., Paul, C., Chapman, K., Twyman, L., Bryant, J., Brozek, I., & Hughes, C. (2014) · BMC Medical Research Methodology · doi:10.1186/1471-2288-14-42 · Cited by 1,467
Barriers to recruiting underrepresented populations to cancer clinical trials: a systematic review
Ford, J. G., Howerton, M. W., Lai, G. Y., Gary, T. L., Bolen, S., Gibbons, M. C., Tilburt, J., Baffi, C., Tanpitukpongse, T. P., Wilson, R. F., et al. (2008) · Cancer · doi:10.1002/cncr.23157 · Cited by 1,083
Self-citationIncreasing Diversity in Clinical Trials: Overcoming Critical Barriers
Clark, L. T., Watkins, L., Piña, I. L., Elmer, M., Akinboboye, O., Gorham, M., Jamerson, B., McCullough, C., Pierre, C., Polis, A. B., et al. (2019) · Current Problems in Cardiology · doi:10.1016/j.cpcardiol.2018.11.002 · Cited by 731
Patient-clinician communication: American Society of Clinical Oncology consensus guideline
Gilligan, T., Coyle, N., Frankel, R. M., Berry, D. L., Bohlke, K., Epstein, R. M., Finlay, E., Jackson, V. A., Lathan, C. S., Loprinzi, C. L., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.75.2311 · Cited by 610
Barriers to Clinical Trial Enrollment in Racial and Ethnic Minority Patients with Cancer
Hamel, L. M., Penner, L. A., Albrecht, T. L., Heath, E., Gwede, C. K., & Eggly, S. (2016) · Cancer Control · doi:10.1177/107327481602300404 · Cited by 463
Metadata
- Authors
- Howerton, M. W., Gibbons, M. C., Baffi, C. R., Gary, T. L., Lai, G. Y., Bolen, S., Tilburt, J., Tanpitukpongse, T. P., Wilson, R. F., Powe, N. R., Bass, E. B., & Ford, J. G.
- Venue
- Cancer
- Publisher
- Wiley
- Published
- 2007-01-02
- Volume
- 109
- Issue
- 3
- Pages
- 465-476
- ISSN
- 0008-543X (ISSN-L)
- 1097-0142
- OpenAlex
- W2075463597
- Cited by
- 184
- References
- 1
- FWCI
- 6.40
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.